Table 6.
Overall levels of evidence per measurement property and PROM
| PROM | Measurement properties | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Content validity | Structural validity | Internal consistency | Reliability | Measurement Error | Hypothesis testing | Criterion validity | Responsiveness | Cross‐cultural validity | |
| Generic | |||||||||
| EQ‐5D | 0 | 0 | 0 | 0 | 0 | −− | 0 | 0 | 0 |
| SF‐36 | 0 | 0 | 0 | 0 | 0 | − | 0 | 0 | 0 |
| WHOQOL‐BREF | 0 | 0 | ? | 0 | 0 | 0 | 0 | 0 | 0 |
| Cancer generic | |||||||||
| EORTC QLQ‐C30 | 0 | 0 | 0 | 0 | 0 | ? | 0 | ++ | 0 |
| Bladder Cancer | |||||||||
| BCI | +++ | ? | ++ | −− | 0 | −− | 0 | ? | ? |
| FACT‐Bl | 0 | ? | ? | 0 | 0 | − | 0 | 0 | ? |
| MIBC | |||||||||
| FACT‐VCI | ? | −− | ++ | ++ | 0 | ++ | 0 | + | ? |
| IONB‐PRO | +++ | + | + | 0 | ? | + | 0 | 0 | 0 |
| EORTC QLQ‐BLM30 | 0 | 0 | ? | 0 | 0 | + | 0 | 0 | 0 |
| Caffo et al. 35 | +++ | ? | ? | 0 | 0 | 0 | 0 | 0 | ? |
| Bjerre et al. 36 | +++ | ? | ? | 0 | 0 | 0 | 0 | 0 | 0 |
| Hart et al. 37 | 0 | 0 | ? | 0 | 0 | 0 | 0 | 0 | 0 |
| Henningsohn et al. 38 | +++ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ? |
| NMIBC | |||||||||
| EORTC QLQ‐NMIBC24 | 0 | ? | + | 0 | 0 | ++ | 0 | −− | 0 |
| CAVICAVENMI | +++ | ++ | ? | ? | 0 | + | 0 | 0 | 0 |
+++, strong evidence positive result; ++ or −−, moderate evidence positive/negative result; + or −, limited evidence positive/negative result; ?, unknown rating, due to poor methodological quality; 0, not assessed.